Richard B. Gaynor

机构：BioNTech (United States)

发表论文 215 篇 · 总被引 19530 次 · h-index 72

代表论文

• A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer (2020 · Cell · 被引 773)
• Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction (2019 · Immunity · 被引 265)
• Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer (2022 · Cancer Cell · 被引 234)
• A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease (2024 · Cell · 被引 161)
• Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes (2020 · Genome Medicine · 被引 101)
• The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection (2023 · Cell · 被引 94)